Keywords: Seattle Geneics, Astellas, Agensys, Milestone, AGS-16M8F
Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
Article | 03 September 2010
US biotechnology firm Seattle Genetics (Nasdaq: SGEN) has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, which ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
